Benlysta gets FDA panel date
This article was originally published in Scrip
The US FDA's arthritis advisory committee will review Human Genome Sciences' investigational lupus drug, Benlysta (belimumab), on 16 November. The product is the first in a new class of drugs called BLyS specific inhibitors and could become the first new treatment of systemic lupus erythematosus (SLE) in 50 years. The product was granted priority status by the FDA last month, which provides for a six-month review instead of the normal 10-month review.